



(11) **EP 2 523 666 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 31/57 ^(2006.01) **A61K 31/575** ^(2006.01)
A61K 47/44 ^(2006.01) **A61P 25/00** ^(2006.01)
C07J 5/00 ^(2006.01) **C07J 9/00** ^(2006.01)

(48) Corrigendum issued on:
06.04.2016 Bulletin 2016/14

(86) International application number:
PCT/SE2011/050036

(45) Date of publication and mention
of the grant of the patent:
13.01.2016 Bulletin 2016/02

(87) International publication number:
WO 2011/087441 (21.07.2011 Gazette 2011/29)

(21) Application number: **11733156.1**

(22) Date of filing: **14.01.2011**

(54) **A PHARMACEUTICAL COMPOSITION COMPRISING
3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY
PROPERTIES**

PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ON
MIT VERBESSERTEN LAGERUNGS- UND LÖSLICHKEITSEIGENSCHAFTEN

COMPOSITION PHARMACEUTIQUE COMPRENANT
3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE A PROPRIETES DE STOCKAGE ET DE
SOLUBILITE AMELIOREES

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

• **CARLSSON, Anders**
S-112 36 Stockholm (SE)

(30) Priority: **14.01.2010 US 295027 P**
14.01.2010 SE 1050029

(74) Representative: **Awapatent AB**
P.O. Box 45086
104 30 Stockholm (SE)

(43) Date of publication of application:
21.11.2012 Bulletin 2012/47

(56) References cited:
WO-A1-99/45931 WO-A2-2006/037016

(73) Proprietor: **Asarina Pharma AB**
171 65 Solna (SE)

• **GONZALEZ-MARISCAL, G. ET AL.:** 'Anesthetic
pregnanes counteract androgen-induced
defeminization.' **NEUROENDOCRINOLOGY** vol.
34, no. 5, 1982, pages 357 - 362

(72) Inventors:
• **BÄCKSTRÖM, Torbjörn**
S-907 38 Umeå (SE)

EP 2 523 666 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).